Education
About Us
Working with TipRanks
Follow Us
Context Therapeutics (CNTX)
NASDAQ:CNTX
CNTX Stock Chart & Stats
$2.86
$0.09(8.26%)
At close: 4:00 PM EST
$2.86
$0.09(8.26%)
Day’s Range― - ―
52-Week Range$0.49 - $2.86
Previous CloseN/A
Volume293.07K
Average Volume (3M)1.58M
Market Cap
$262.77M
Enterprise Value$209.87M
Total Cash (Recent Filing)$76.94M
Total Debt (Recent Filing)$140.20K
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Mar 25, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding91,879,170
10 Day Avg. Volume657,422
30 Day Avg. Volume1,580,908
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-2.09
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-51.61K
Enterprise Value/Ebitda-7.17
Forecast
1Y Price Target
$5.75Price Target Upside101.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data PotentialClinical readouts from two early-stage trials could validate the pipeline if they demonstrate efficacy at low doses with manageable safety, improving investor risk/reward perceptions.
Target SpecificityLead program targets CLDN6, an oncofetal antigen with restricted normal tissue expression, which reduces target-related safety risk and supports development confidence.
Therapeutic Class ValidationEmerging T-cell engager therapies show increasing validation in solid tumors, which could broaden clinical interest and support potential market adoption.
Bears Say
Analyst Conflict Of InterestDisclosed commercial relationships between the research firm and covered companies create potential conflicts that may reduce the objectivity of analyst reports and increase stock volatility.
Context Therapeutics News
CNTX FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was $0.49 and its highest was $2.86 in the past 12 months.
What is Context Therapeutics’s market cap?
Context Therapeutics’s market cap is $262.77M.
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is Mar 25, 2026 which is in 18 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.088 by -$0.012.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 91,879,170 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.088. Following the earnings report the stock price went down -5.31%.
Which hedge fund is a major shareholder of Context Therapeutics?
Currently, no hedge funds are holding shares in CNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Context Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.75 (101.05% Upside)
$5.75 (101.05% Upside)
Blogger Sentiment
Bullish
CNTX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
239.66%
12-Months-Change
Fundamentals
Return on Equity
-33.68%
Trailing 12-Months
Asset Growth
-8.22%
Trailing 12-Months
Company Description
Context Therapeutics
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CNTX Stock 12 Month Forecast
Average Price Target
$5.75
▲(101.05% Upside)
Technical Analysis
Ownership Overview
1.35% Insiders
5.63% Mutual Funds
53.70% Other Institutional Investors
35.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---